Tag

Recurring Revenue

All articles tagged with #recurring revenue

Space as a Service: Invest in Networks, Not Just Rockets
opinion18 days ago

Space as a Service: Invest in Networks, Not Just Rockets

The article argues that space is shifting from one-off hardware bets to a networked, service-based model. With thousands of satellites and fleets like Starlink, space infrastructure now provides ongoing connectivity, Earth observation, and secure communications. Investors should focus on companies that own or operate space networks and deliver recurring revenue (not just single-component suppliers), diversify across the value chain to reduce risk, and push for clear regulatory rules to enable long-term planning as the space economy could reach trillions by 2035.

Micron’s AI-fueled Rally Faces Inevitable Reversion to Mean
markets2 months ago

Micron’s AI-fueled Rally Faces Inevitable Reversion to Mean

The analysis argues Micron’s current stock surge reflects a temporary, cyclical memory-demand spike driven by AI, not lasting growth. As memory capacity expands, margins and earnings are likely to retrace, making MU overvalued versus secular growers with recurring revenues (e.g., data-center REITs like Equinix) and utilities. The piece highlights how capacity expansions have historically crushed cyclical highs, and Micron’s own capex plan will boost supply further, supporting a return to equilibrium rather than permanent gains. Investors should rotate from MU’s immediate-revenue burst to companies with durable, recurring revenue.

Novavax and Moderna Compete in Dual COVID-19/Flu Vaccine Trials
business2 years ago

Novavax and Moderna Compete in Dual COVID-19/Flu Vaccine Trials

Novavax, a smaller rival to Moderna and Pfizer in the COVID-19 vaccine market, may have a better chance of gaining market share with its updated coronavirus vaccine. As the vaccine landscape shifts to a commercial model, Novavax could carve out a market share by rapidly delivering doses to customers. This opportunity is crucial as the coronavirus is expected to stay, creating a potential market for annual vaccine sales. Novavax's presence in the vaccine marketplace now could also position it well for a potential combined flu/coronavirus vaccine product in the future. Investors should monitor Novavax's progress and consider the long-term rewards of its vaccine innovation.